Emergent BioSolutions Looks to the Second Half for Growth
Emergent BioSolutions (NYSE: EBS) continued its transition in the second quarter with another loss on the earnings line. Fortunately, the bioterrorism expert shouldn't take too long to turn things around, because earnings growth is expected in the second half of this year.
Metric
Q2 2019
Quelle Fool.com